Ultragenyx Pharmaceutical (RARE) : The total money flow in Ultragenyx Pharmaceutical (RARE) was negative ($1.4 million), which signals selling by the traders on Wednesdays session. They trimmed their holdings by selling the stock on downticks to the tune of $2.44 million. In comparison, the inflow of money into the stock on upticks was $1.04 million. The uptick to downtick ratio was 0.43. Similarly, the block trades show selling by large traders on strength. The value of stocks sold down on downtick was $0 million. The negative money flow of ($0 million) confirms the selling in Ultragenyx Pharmaceutical (RARE) on strength. Ultragenyx Pharmaceutical (RARE) gained $0.34 at $73.08, a gain of 0.47% over the previous days close. However, the stock registered 0.66% in the week.
Ultragenyx Pharmaceutical Inc. has dropped 3.02% in the last five trading days, however, the shares have posted positive gains of 10.06% in the last 4 weeks. Ultragenyx Pharmaceutical Inc. is up 43.84% in the last 3-month period. Year-to-Date the stock performance stands at -36.21%.
Ultragenyx Pharmaceutical (RARE) has an average broker rating of 1.23, which is interpreted as a Strong Buy, as rated by 13 equity analysts. Nonetheless, 11 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. 1 other analysts advise a Buy. Nevertheless, the majority of 1 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.
Ultragenyx Pharmaceutical (NASDAQ:RARE): stock was range-bound between the intraday low of $70.27 and the intraday high of $73.83 after having opened at $72.71 on Wednesdays session. The stock finally closed in the red at $72.71, a loss of -1.62%. The stock remained in the red for the whole trading day. The total traded volume was 449,679 shares. The stock failed to cross $73.83 in Wednesdays trading. The stocks closing price on Thursday was $72.74.
Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Its pipeline consists of two product categories: biologics, including a monoclonal antibody and enzyme replacement therapies, and small-molecule substrate replacement therapies. Its products are KRN23 (UX023), rhGUS (UX003), rhPPCA (UX004), Triheptanoin (UX007) and SA-ER (UX001). KRN23 is a fully human monoclonal antibody administered via subcutaneous injection. rhGUS is an intravenous (IV), enzyme replacement therapy for the treatment of mucopolysaccharidosis 7. rhPPCA is an enzyme replacement therapy for galactosialidosis. Triheptanoin is a medium odd-chain triglyceride of seven-carbon fatty acids. SA-ER is for the treatment of hereditary inclusion body myopathy (HIBM).